Multiple Myeloma KarMMA Trial Methodology: Larry Anderson, MD

Video

The associate professor from Harold C. Simmons Comprehensive Cancer Center discussed the methodology of the phase 2 KarMMa trial.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Larry Anderson, MD, PhD, associate professor, Department of Internal Medicine, Division of Hematology/Oncology, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, about the methods utilized in the phase 2 KarMMa trial (NCT03361748) in multiple myeloma (MM).

The KarMMa trial investigated the efficacy and safety of idecabtagene vicleucel (ide-cel; Abecma) in patients with relapsed/refractory MM. Updated data was presented at the 2021 International Myeloma Workshop.

Prior to ide-cel administration, peripheral blood autologous T cells are taken via leukapheresis from a patient and modified with a viral vector to express a CAR T-cell receptor that recognizes BCMA, a plasma cell–specific surface protein on myeloma cells that is not expressed on other normal tissue, Anderson explains. In the KarMMa trial, 128 patients with relapsed/refractory multiple myeloma who received at least 3 prior lines of therapy were treated with ide-cel across a target dose range of 150 x 106 to 450 x 106 CAR T cells, Anderson adds. Patients had received a median of 6 prior lines of therapy, with a range from 3 to 16, Anderson concludes.

Related Videos
Paula Cannon, PhD, the president elect of ASGCT and a distinguished professor of microbiology at Keck School of Medicine of USC
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
© 2024 MJH Life Sciences

All rights reserved.